Geode Capital Management LLC Has $6.54 Million Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Geode Capital Management LLC raised its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 3.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 640,350 shares of the company’s stock after purchasing an additional 20,092 shares during the quarter. Geode Capital Management LLC’s holdings in iTeos Therapeutics were worth $6,540,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ITOS. Candriam S.C.A. purchased a new position in shares of iTeos Therapeutics during the 2nd quarter valued at $7,558,000. State Street Corp boosted its position in iTeos Therapeutics by 21.9% during the third quarter. State Street Corp now owns 1,175,353 shares of the company’s stock valued at $12,000,000 after purchasing an additional 211,452 shares during the last quarter. Clearline Capital LP purchased a new position in iTeos Therapeutics in the second quarter valued at about $2,328,000. Algert Global LLC increased its position in iTeos Therapeutics by 92.0% in the 3rd quarter. Algert Global LLC now owns 256,139 shares of the company’s stock worth $2,615,000 after purchasing an additional 122,730 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of iTeos Therapeutics by 14.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock worth $13,481,000 after purchasing an additional 117,159 shares in the last quarter. Hedge funds and other institutional investors own 97.16% of the company’s stock.

Insider Buying and Selling

In other news, CFO Matthew Gall purchased 5,000 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was bought at an average cost of $7.73 per share, for a total transaction of $38,650.00. Following the completion of the acquisition, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. The trade was a 8.27 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 12.50% of the company’s stock.

iTeos Therapeutics Stock Performance

Shares of ITOS stock opened at $8.15 on Friday. The stock’s 50 day simple moving average is $8.21 and its 200 day simple moving average is $12.03. iTeos Therapeutics, Inc. has a twelve month low of $7.09 and a twelve month high of $18.75. The company has a market capitalization of $297.75 million, a price-to-earnings ratio of -2.59 and a beta of 1.37.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.13. On average, analysts forecast that iTeos Therapeutics, Inc. will post -3.46 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on ITOS shares. Wells Fargo & Company lowered their price target on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th. Wedbush reissued an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a research report on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of iTeos Therapeutics in a report on Friday, December 13th.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.